[Corrigendum] Zoledronic acid sensitizes breast cancer cells to fulvestrant via ERK/HIF‑1 pathway inhibition in vivo.

Following the publication of the above article, the authors drew to the Editor's attention that they had inadvertently used the same immunohistochemical image to show the experiments depicting the zoledronic acid‑treated MCF‑7/HIF‑1α xenograft (the 'ZOL/MCF‑7/hif' panel) and the fulvestrant‑treated MCF‑7/vector xenograft (the 'FUL/MCF‑7/cdh' panel) in Fig. 3A on p. 5474. Subsequently, upon performing an independent review of the data in this paper, the Editorial Office pointed out to the authors that the same colony‑formation assay image had been included in Fig. 1C to show the 'MCF‑7/cdh‑ZOL' and 'MCF‑7/cdh‑FUL' experiments. The authors re‑examined their original data, and realized that inadvertent errors were made during the compilation of this pair of figures. The corrected versions of Figs. 1 and 3 are shown on the next two pages, now featuring the correct data for the 'MCF‑7/cdh‑ZOL' experiment in Fig. 1C and the 'ZOL/MCF‑7/hif' experiment in Fig. 3A. All the authors agree with the publication of this corrigendum, and are grateful to the Editor of Molecular Medicine Reports for granting them the opportunity to publish this. Furthermore, they regret that these errors were introduced into the paper, even though they did not substantially alter any of the major conclusions reported in the paper, and apologize to the readership for any inconvenience caused. [Molecular Medicine Reports 17: 5470‑5476, 2018; DOI: 10.3892/mmr.2018.8514].